Pfizer ( PFE) shares gained on Tuesday after the New York-based pharma giant reported better-than-expected financials for Q2 2025 and increased its full-year earnings outlook, citing, among other ...

The Food and Drug Administration (FDA) is hitting some speed bumps in implementing the Trump campaign agenda, and the ...

Less than weeks after stepping down, Prasad will return to lead CBER “at the FDA’s request,” according to an HHS spokesperson ...

Vinay Prasad, who was recently ousted as the top vaccine and gene therapy regulator at the US Food and Drug Administration, is returning to his role, the Department of Health and Human Services said ...

Sarepta reported a quarter-on-quarter dip in sales for its Duchenne gene therapy. Elsewhere, Jazz won FDA approval of a brain cancer drug and Novo decided to advance a Prothena medicine into Phase 3.

Sarepta Therapeutics Inc.’s shares soared after the US biotech reported revenue that beat estimates, which analysts ...

The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...

Wells’ new price target of $50 implies nearly 208% upside potential from the stock’s closing price on Wednesday.

Sarepta did not hold an investor call for its second-quarter earnings report or provide an updated full-year revenue outlook.

One of the most notable accomplishments of the first Trump Administration was its willingness to take on the status quo of ...

After a second Elevidys patient death from acute liver failure, Sarepta in July launched a major restructuring that involves ...

Sarepta Therapeutics (SRPT) stock in focus as report says company hired a Trump-linked lobbying firm after deaths linked to ...